FDA Drafts New Recommendations for More Inclusive Pulse Oximeter Testing
By Physician’s Briefing Staff HealthDay Reporter
TUESDAY, Jan. 7, 2025 -- The U.S. Food and Drug Administration released draft guidelines on Jan. 6 proposing that manufacturers conduct larger, more inclusive studies to ensure pulse oximeters work for people with darker skin.
Among the key changes, the new recommendations call for enrolling at least 150 patients with diverse skin tones in clinical studies; increasing representation of patients with darker skin to at least 25 percent in each study, up from 15 percent; and using multiple methods to evaluate skin pigmentation, including scientific measurements of melanin.
The proposal applies only to professional pulse oximeters used in medical settings, such as hospitals and clinics. Over-the-counter oximeters, often marketed as "general wellness" devices, are not affected.
The FDA recommendations come after studies, including one from 2021, revealed that pulse oximeters often overestimate oxygen levels in Black patients, potentially delaying treatment and increasing health risks, a news release states.
Existing devices already on the market will not need to meet these new standards unless manufacturers request updates or modifications.
The FDA will accept public comments on the draft proposal for 60 days before finalizing the guidelines.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-01-09 00:00
Read more
- Vitamin D Supplementation Does Not Reduce Risk for T2DM in Healthy Seniors
- Singapore Is Ready for a Rapidly Aging Society, Study Says. What About the U.S.?
- Non-heterosexual Women Report Better Sexual Functioning During Midlife
- Tevimbra Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
- Tea and Coffee May Help Protect You From Some Cancers
- In Kids with Crohn's Disease, TNF Inhibitors Help Prevent Serious Complications, Data Suggests
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions